NCT06593938View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 25, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

HRS-5965 capsule

HRS-5965 capsule for 24 weeks

DRUG

Eculizumab Injection

Eculizumab Injection for 24 weeks

Trial Locations (2)

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

300020

The Blood Disease Hospital of the Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors

lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY

NCT06593938 - A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy | Biotech Hunter | Biotech Hunter